Cargando…
De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
The programmed cell death ligand-1 antibody, atezolizumab, is an immune checkpoint inhibitor approved for the treatment of various cancers. Herein, we describe a case of an 87-year-old man with advanced urothelial carcinoma. After surgery, atezolizumab was given. Subsequently, he developed generaliz...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713254/ https://www.ncbi.nlm.nih.gov/pubmed/31497433 http://dx.doi.org/10.7759/cureus.5002 |